Russell Harris, MD, MPH; Kathleen N. Lohr, PhD
In U.S. men, prostate cancer is the most common noncutaneous cancer and the second leading cause of cancer death. Screening for prostate cancer is controversial.
To examine for the U.S. Preventive Services Task Force the evidence of benefits and harms of screening and earlier treatment.
MEDLINE and the Cochrane Library, experts, and bibliographies of reviews.
Researchers developed eight questions representing a logical chain between screening and reduced mortality, along with eligibility criteria for admissible evidence for each question. Admissible evidence was obtained by searching the data sources.
Two reviewers abstracted relevant information using standardized abstraction forms and graded article quality according to Task Force criteria.
No conclusive direct evidence shows that screening reduces prostate cancer mortality. Some screening tests can detect prostate cancer at an earlier stage than clinical detection. One study provides good evidence that radical prostatectomy reduces disease-specific mortality for men with localized prostate cancer detected clinically. No study has examined the additional benefit of earlier treatment after detection by screening. Men with a life expectancy of fewer than 10 years are unlikely to benefit from screening even under favorable assumptions. Each treatment is associated with several well-documented potential harms.
Although potential harms of screening for prostate cancer can be established, the presence or magnitude of potential benefits cannot. Therefore, the net benefit of screening cannot be determined.
The number of cancer cases detected would be smaller after repeated annual screening. * For men in their 50s, = 50; for men in their 70s, = 270. † For men in their 50s, = 150; for men in their 70s, = 400. ‡ For men in their 50s, = 17; for men in their 70s, = 90. § For men in their 50s, = 30; for men in their 70s, = 100. ‖For men in their 50s, = 12; for men in their 70s, = 63. ¶ For men in their 50s, = 21; for men in their 70s, = 70. In all footnotes, numbers are approximate.
The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.
Harris R, Lohr KN. Screening for Prostate Cancer: An Update of the Evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002;137:917–929. doi: 10.7326/0003-4819-137-11-200212030-00014
Download citation file:
Published: Ann Intern Med. 2002;137(11):917-929.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only